Phil Skolnick

Indivior (United States) — United States

Neuroscience · Life Sciences

83h-index26.6kcitations530works4.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroscience and Neuropharmacology Research(306), Receptor Mechanisms and Signaling(92), Neurotransmitter Receptor Influence on Behavior(91), Ion channel regulation and function(64), Treatment of Major Depression(43)

Publications530 total

Response to: improvements to out-of-hospital cardiac arrest and opioid overdose treatment algorithms to enhance positive outcomes
Emergency and Critical Care Medicine·2025Open Access
Post-marketing Surveillance of Intranasal Nalmefene: Prevalence and Clinical Relevance of Precipitated Withdrawal
Cureus·2025Open Access
Reversal of a synthetic opioid overdose: Insights from a validated translational model
Neuropharmacology·2025· 1 cited
Translational Modeling as a Tool to Evaluate the Effectiveness of Nalmefene in a Community Setting: A Critical Perspective
Clinical Pharmacology & Therapeutics·2025Open Access
Comparative Effectiveness of Intranasal Naloxone and Nalmefene in a Translational Model Assessing Reversal of Cardiac Arrest Induced by Synthetic Opioid Overdose
Drug and Alcohol Dependence·2025
Synthetic opioids have disrupted conventional wisdom for treating opioid overdose
Drug and Alcohol Dependence Reports·2024· 12 citedOpen Access
Editorial: Discovery, development and implementation of improved options for treating opioid overdose in the synthetic opioid era
Frontiers in Psychiatry·2024Open Access
Comparison of intranasal naloxone and intranasal nalmefene in a translational model assessing the impact of synthetic opioid overdose on respiratory depression and cardiac arrest
Frontiers in Psychiatry·2024· 13 citedOpen Access
Reversal of Opioid‐Induced Respiratory Depression in Healthy Volunteers: Comparison of Intranasal Nalmefene and Intranasal Naloxone
The Journal of Clinical Pharmacology·2024· 16 citedOpen Access
Comment on: Can Intranasal Nalmefene Reduce the Number of Opioid Overdose Deaths?
Clinical Pharmacology in Drug Development·2024· 2 citedOpen Access
Pharmacokinetic Properties of an FDA‐approved Intranasal Nalmefene Formulation for the Treatment of Opioid Overdose
Clinical Pharmacology in Drug Development·2023· 27 citedOpen Access
Treatment of overdose in the synthetic opioid era
Pharmacology & Therapeutics·2021· 112 citedOpen Access
Anxiety: Mechanisms and Management
2021
Countermeasures for Preventing and Treating Opioid Overdose
Clinical Pharmacology & Therapeutics·2020· 66 citedOpen Access
Cannabinoid1 (CB-1) receptor antagonists: a molecular approach to treating acute cannabinoid overdose
Journal of Neural Transmission·2019· 8 citedOpen Access
Be positive about negatives–recommendations for the publication of negative (or null) results
European Neuropsychopharmacology·2019· 51 citedOpen Access
Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects
Drug Metabolism and Disposition·2019· 13 citedOpen Access
Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose
Journal of Pharmacology and Experimental Therapeutics·2019· 53 citedOpen Access
Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose
The Journal of Clinical Pharmacology·2019· 15 citedOpen Access
On the front lines of the opioid epidemic: Rescue by naloxone
European Journal of Pharmacology·2018· 59 citedOpen Access
page 1 of 27Next →

Frequent Co-authors

Steven M. Paul(17), Piotr Popik(6), Richard T. Layer(5), Anthony S. Basile(5), Jacqueline N. Crawley(4), Ramón Trullás(4), Frederick K. Goodwin(4), Gabriel Nowak(3), Moshe Rehavi(3), Xia Li(3), Peter J. Syapin(3), Soumen Paul(3), E. Anthony Jones(3), Kenner C. Rice(3), Aaron Janowsky(3), Eric A. Barnard(2), R. W. Olsen(2), H Möhler(2), Werner Sieghart(2), Giovanni Biggio(2)